Yahoo Suche Web Suche

Suchergebnisse

1. Suchergebnisse:

1. www.finanznachrichten.de › nachrichten-2024-05 › 62376731Verve Therapeutics Announces Leadership Update -...

   www.finanznachrichten.de › nachrichten-2024-05 › 62376731

   • Im Cache

   Vor 13 Stunden · Troy Lister, Ph.D., to be promoted to chief scientific officer Andrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory capacity BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve

2. Videos

   • 

     discogs.com

     The Verve - Forth

     19. Okt. 2021

     3M Aufrufe

   • 

     discogs.com

     The Verve - Forth

     17. Okt. 2021

     4.8M Aufrufe

   • 

     discogs.com

     The Verve - Forth

     28. Okt. 2021

   Alle anzeigen

3. de.marketscreener.com › kurs › aktieVerve Therapeutics, Inc. kündigt Änderungen in der...

   de.marketscreener.com › kurs › aktie

   • Im Cache

   Vor 13 Stunden · VERVE-101 und VERVE-102 sind so konzipiert, dass sie das PCSK9-Gen in der Leber dauerhaft ausschalten und werden zunächst für die heterozygote familiäre Hypercholesterinämie (HeFH) entwickelt. VERVE-201 soll das ANGPTL3-Gen in der Leber dauerhaft ausschalten und wird zunächst für die homozygote familiäre Hypercholesterinämie (HoFH) und für die refraktäre Hypercholesterinämie ...

4. stockhouse.com › news › press-releases2024-05-31 | Verve Therapeutics Announces Leadership Update -...

   stockhouse.com › news › press-releases

   • Im Cache

   Vor 13 Stunden · BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Troy Lister, Ph.D., currently serving as Verve’s senior vice president, research and early development, has been ...

5. finance.yahoo.com › news › verve-therapeutics-announcesVerve Therapeutics Announces Pipeline Progress and Reports First...

   finance.yahoo.com › news › verve-therapeutics-announces

   • Im Cache

   8. Mai 2024 · BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...

6. www.marketscreener.com › quote › stockVerve Therapeutics Announces Leadership Update - MarketScreener

   www.marketscreener.com › quote › stock

   • Im Cache

   Vor 2 Stunden · Verve Therapeutics Announces Leadership Update. May 31, 2024 at 07:00 am EDT. Troy Lister, Ph.D., to be promoted to chief scientific officer. Andrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory capacity. BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a ...

7. www.stocktitan.net › news › VERVVerve Therapeutics Announces Leadership Update | $VERV Stock News

   www.stocktitan.net › news › VERV

   • Im Cache

   Vor 13 Stunden · Rhea-AI Summary. Verve Therapeutics has announced a leadership update with Troy Lister, Ph.D., being promoted to Chief Scientific Officer (CSO), effective June 21, 2024. Lister has been with Verve for two years, bringing over 15 years of experience, including roles at Spero Therapeutics, Novartis, and AstraZeneca.

8. ir.vervetx.com › news-releases › news-release-detailsVerve Therapeutics Announces Pipeline Progress and Reports First...

   ir.vervetx.com › news-releases › news-release-details

   • Im Cache

   8. Mai 2024 · BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported pipeline updates and financial results for the quarter ended March 31, 2024.